**Author details**

Aqsa Nazir1 \*, Muhammad Aqib2 and Muhammad Usman<sup>2</sup>

1 Institute of Food Science and Technology, University of Agriculture Faisalabad, Pakistan

2 Department Nutritional Sciences, Government College University, Faisalabad, Pakistan

\*Address all correspondence to: maqibniaz595@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Etiology, Mechanism and Treatment of Liver Cancer DOI: http://dx.doi.org/10.5772/intechopen.106020*

## **References**

[1] Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death & Disease. 2020;**11**(5):1-13

[2] World Health Organization. Projections of Mortality and Causes of Death, 2016 to 2060. Geneva, Switzerland: World Health Organization; 2020 Available from: http://www.who. int/healthinfo/global\_burden\_disease/ projections/en/

[3] Liu C-Y, Chen K-F, Chen P-J. Treatment of liver cancer. Cold Spring Harbor Perspectives in Medicine. 2015;**5**(9):a021535

[4] Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice. Clinical Gastroenterology and Hepatology. 2015;**13**(12):2140-2151

[5] Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Current epidemiology reports. 2019;**6**(2):104-111

[6] Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The liver cancer pooling project. British Journal of Cancer. 2018;**118**(7):1005-1012

[7] Lushniak BD, Samet JM, Pechacek TF, Norman LA, Taylor PA. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA, USA: Centers for disease control and Prevention; 2014

[8] Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA, et al. Aflatoxin and the aetiology of liver cancer and its implications for Guatemala. World Mycotoxin Journal. 2021;**14**(3):305-317

[9] Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, et al. Mechanisms of hepatocellular carcinoma progression. World Journal of Gastroenterology. 2019;**25**(19):2279

[10] Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and metaanalysis. Clinical Gastroenterology and Hepatology. 2017;**15**(8):1207-1217

[11] Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nature Reviews Cancer. 2015;**15**(11):653-667

[12] Refolo MG, Messa C, Guerra V, Carr BI, D'alessandro R. Inflammatory mechanisms of HCC development. Cancers. 2020;**12**(3):641

[13] Yang YM, Kim SY, Seki E. Inflammation and liver cancer: Molecular mechanisms and therapeutic targets. In: Seminars in Liver Disease. Vol. 39, No. 1. New York, NY, USA: Thieme Medical Publishers; 2019. pp. 26-42

[14] Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. Journal of Hepatology. 2014;**60**(2):346-353

[15] Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver cancer: Therapeutic challenges and the importance of experimental models. Canadian Journal of Gastroenterology and Hepatology. 2021;**2021**:8837811

[16] Guo L, Teng L. YAP/TAZ for cancer therapy: Opportunities and challenges. International Journal of Oncology. 2015;**46**(4):1444-1452

[17] Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. Journal of hepatocellular carcinoma. 2018;**5**:61

[18] Czauderna C, Castven D, Mahn FL, Marquardt JU. Context-dependent role of NF-κB signaling in primary liver cancer—From tumor development to therapeutic implications. Cancers. 2019;**11**(8):1053

[19] McVicker BL, Hamel FG, Simpson RL, Bennett RG. A selective PPARγ modulator reduces hepatic fibrosis. Biology. 2020;**9**(7):151

[20] Dong Y, Wang A. Aberrant DNA methylation in hepatocellular carcinoma tumor suppression. Oncology Letters. 2014;**8**(3):963-968

[21] Heo MJ, Yun J, Kim SG. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. Archives of Pharmacal Research. 2019;**42**(1):48-62

[22] Liu Y-X, Li Q-Z, Cao Y-N, Zhang L-Q. Identification of key genes and important histone modifications in hepatocellular carcinoma. Computational and Structural Biotechnology Journal. 2020;**18**:2657-2669

[23] Svinka J, Mikulits W, Eferl R. STAT3 in hepatocellular carcinoma: New perspectives. Hepatic Oncology. 2014;**1**(1):107-120

[24] Wang N, Wang S, Li M-Y, Hu B-g, Liu L-p, Yang S-l, et al. Cancer stem cells in hepatocellular carcinoma: An overview and promising therapeutic strategies. Therapeutic Advances in Medical Oncology. 2018;**10**:1-25

[25] Yin F, Han X, Yao S-K, Wang X-L, Yang H-C. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma. World Journal of Gastroenterology. 2016;**22**(9):2837

[26] Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics. 2012;**44**(6):694-698

[27] Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Developmental Cell. 2010;**19**(1):27-38

[28] Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nature Cell Biology. 2014;**16**(10):972-981

[29] Marquardt JU, Gomez-Quiroz L, Arreguin LO, Camacho FP, Lee Y-H, Kitade M, et al. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. Journal of Hepatology. 2015;**63**(3):661-669

[30] Jiang J-W, Chen X-H, Ren Z, Zheng S-S. Gut microbial dysbiosis associates

*Etiology, Mechanism and Treatment of Liver Cancer DOI: http://dx.doi.org/10.5772/intechopen.106020*

hepatocellular carcinoma via the gutliver axis. Hepatobiliary & Pancreatic Diseases International. 2019;**18**(1): 19-27

[31] Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clinical Infectious Diseases. 2018;**67**(6):869-877

[32] Wang J, Yang Wang X, Zhang JL, Qianpeng Zhang Y, Zhao JP, et al., editors. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Frontiers in Microbiology. 2017;**8**:2222

[33] Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;**53**(1):96-105

[34] Shen F, Zheng R-D, Sun X-Q, Ding W-J, Wang X-Y, Fan J-G. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International. 2017;**16**(4):375-381

[35] Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;**513**(7516):59-64

[36] Ren Z, Li A, Jiang J, Lin Z, Yu Z, Lu H, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;**68**(6):1014-1023

[37] Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Spurnic AR, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature. International Journal of Molecular Sciences. 2019;**20**(2):395

[38] Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Letters. 2020;**474**:15-22

[39] Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: Etiology and current and future drugs. Journal of Clinical and Experimental Hepatology. 2019;**9**(2):221-232

[40] Kamiyama T, Tahara M, Nakanishi K, Yokoo H, Kamachi H, Kakisaka T, et al. Long-term outcome of laparoscopic hepatectomy in patients with hepatocellular carcinoma. Hepato-Gastroenterology. 2014;**61**(130):405-409

[41] Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: A meta-analysis of 23 studies. Journal of Cancer Research and Clinical Oncology. 2015;**141**(1):1-9

[42] Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020;**1873**(1):188314

[43] Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nature Biotechnology. 2012;**30**(7):658-670

[44] Ballout F, Habli Z, Rahal ON, Fatfat M, Gali-Muhtasib H. Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges. Drug Discovery Today. 2018;**23**(5):1089-1098

## **Chapter 2**
